You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

DUODOTE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Duodote, and what generic alternatives are available?

Duodote is a drug marketed by MMT and is included in one NDA.

The generic ingredient in DUODOTE is atropine; pralidoxime chloride. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the atropine; pralidoxime chloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DUODOTE?
  • What are the global sales for DUODOTE?
  • What is Average Wholesale Price for DUODOTE?
Summary for DUODOTE
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 5
Patent Applications: 199
What excipients (inactive ingredients) are in DUODOTE?DUODOTE excipients list
DailyMed Link:DUODOTE at DailyMed
Drug patent expirations by year for DUODOTE

US Patents and Regulatory Information for DUODOTE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mmt DUODOTE atropine; pralidoxime chloride INJECTABLE;INTRAMUSCULAR 021983-001 Sep 28, 2006 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DUODOTE

See the table below for patents covering DUODOTE around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0525048 AUTO-INJECTEUR DE DISPERSION A PLUSIEURS CHAMBRES (DISPERSION MULTI-CHAMBER AUTO-INJECTOR) ⤷  Subscribe
Australia 7675591 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 9116094 ⤷  Subscribe
Germany 69126661 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

DUODOTE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for DuoDote

Introduction

DuoDote, a brand name for the combination of atropine and pralidoxime chloride, is a critical medical countermeasure used to treat nerve agent poisoning. Here, we delve into the market dynamics and financial trajectory of this essential drug.

FDA Approval and Formulation

DuoDote was approved by the FDA on September 28, 2006, and is manufactured by Meridian Medical Technologies (MMT), a division of Kindeva Drug Delivery. It is available in a dual-chamber autoinjector formulation, making it a convenient and rapid treatment option for chemical nerve agent exposure[1].

Market Availability

As of the latest updates, there is no generic version of DuoDote available in the United States. This lack of generic competition means that MMT maintains a monopoly on the market for this specific formulation, which can influence pricing and availability[1].

Supply Contracts and Government Support

Meridian Medical Technologies has secured significant contracts to supply DuoDote to various entities, including the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. A recent contract valued at $9.9 million highlights the ongoing demand and government support for this drug[2].

Expiration Date Extensions and Supply Disruptions

The FDA has played a crucial role in managing the supply of DuoDote by extending the expiration dates of certain lots due to supply disruptions. However, these extensions have now ceased, and stakeholders are advised to replace and dispose of outdated units. This management of expiration dates reflects the delicate balance between ensuring availability and maintaining product safety[4].

Financial Implications of Supply and Demand

The absence of generic alternatives and the critical nature of DuoDote in emergency response scenarios contribute to its financial stability. The drug's market is less subject to the typical pressures of generic competition, which often drive prices down. Instead, the demand from government and emergency response agencies helps maintain a steady financial trajectory for the manufacturer[2].

Funding for Homeland Security and Emergency Response

The financial trajectory of DuoDote is also influenced by broader trends in homeland security funding. Federal grants for homeland security have been declining, which can impact the purchasing power of state and local agencies. However, specific allocations for critical medical countermeasures like DuoDote often remain a priority, ensuring continued financial support[5].

Impact of Declining Federal Grants

Despite the overall decline in federal homeland security grants, states like Illinois have increased their own contributions to maintain preparedness. This includes funding for equipment replacement and training, which indirectly supports the market for essential drugs like DuoDote. The stability in state funding helps mitigate the effects of federal budget reductions[5].

Capital Replacement and Equipment Needs

The need for capital replacement of aging equipment, including medical countermeasures like DuoDote, is a significant financial challenge. States and local governments face difficulties in replacing outdated equipment due to reduced federal funding, which can affect the long-term availability and effectiveness of these critical drugs[5].

Industry Dynamics and Innovation

The pharmaceutical industry, particularly the segment dealing with emergency response and chemical countermeasures, is characterized by continuous innovation and shifting product lifecycles. While older therapies may lose importance as they go off-patent, innovative products like DuoDote continue to play a vital role, driving spending in their respective therapy areas[3].

Safety and Regulatory Considerations

The FDA's role in ensuring the safety and efficacy of DuoDote is crucial. Alerts regarding expiration date extensions and the proper disposal of outdated units highlight the regulatory scrutiny this drug is under. Compliance with FDA guidelines is essential for maintaining market trust and ensuring the drug's continued availability[4].

Market Share and Competition

Given the lack of a generic version, DuoDote holds a unique position in the market for nerve agent antidotes. This monopoly allows MMT to maintain a significant market share, although it also raises concerns about potential price gouging and the need for continued regulatory oversight to ensure fair market practices[1].

Future Outlook

The future financial trajectory of DuoDote is likely to remain stable due to its critical role in emergency response and the ongoing support from government contracts. However, the broader trends in homeland security funding and the need for capital replacement will continue to influence the market dynamics. As innovation in medical countermeasures continues, DuoDote is expected to remain a key player in the field of chemical nerve agent treatment.

Key Takeaways

  • DuoDote is a brand name for the combination of atropine and pralidoxime chloride, approved by the FDA in 2006.
  • There is currently no generic version available in the United States.
  • Significant supply contracts, including a $9.9 million contract with ASPR, support the drug's market.
  • FDA extensions of expiration dates have ceased, and outdated units must be replaced.
  • Declining federal grants for homeland security impact state and local purchasing power but do not significantly affect DuoDote's financial stability.
  • The need for capital replacement of aging equipment remains a financial challenge.
  • Regulatory oversight by the FDA ensures the drug's safety and efficacy.

FAQs

Q: Is there a generic version of DuoDote available?

A: No, there is currently no therapeutically equivalent generic version of DuoDote available in the United States[1].

Q: Who manufactures DuoDote?

A: DuoDote is manufactured by Meridian Medical Technologies (MMT), a division of Kindeva Drug Delivery[1].

Q: What is the significance of FDA expiration date extensions for DuoDote?

A: The FDA has extended the expiration dates of certain lots of DuoDote due to supply disruptions. However, these extensions have now ceased, and outdated units must be replaced and disposed of properly[4].

Q: How does federal funding impact the market for DuoDote?

A: Declining federal grants for homeland security can affect state and local agencies' purchasing power, but specific allocations for critical medical countermeasures like DuoDote often remain a priority, ensuring continued financial support[5].

Q: What are the key challenges in maintaining the supply of DuoDote?

A: The key challenges include the need for capital replacement of aging equipment, ensuring compliance with FDA guidelines, and managing supply disruptions to maintain availability[4][5].

Sources

  1. Generic DuoDote Availability - Drugs.com
  2. DuoDote® Supply Contract - Kindeva Drug Delivery
  3. Understanding the Dynamics of Drug Expenditure - IQVIA
  4. Expiration date extensions of certain auto-injectors - FDA
  5. 2023 Illinois Homeland Security Advisory Council Annual Report

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.